Asymmetric dimethylarginine: A novel marker of risk and a potential target for therapy in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 6, 2008, Pages 609-615

  Kielstein, Jan T ^a   Zoccali, Carmine ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Asymmetric dimethylarginine; Chronic kidney disease; Dimethylamine dimethylaminohydrolase; Symmetrical dimethylarginine

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

BRAIN PERFUSION; CARDIOGENIC SHOCK; CHRONIC KIDNEY DISEASE; DIAGNOSTIC VALUE; DISEASE MARKER; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; NOCICEPTION; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

AMIDOHYDROLASES; ANIMALS; ARGININE; BIOLOGICAL MARKERS; CHRONIC DISEASE; DISEASE PROGRESSION; GENE THERAPY; GLOMERULAR FILTRATION RATE; GROWTH HORMONE; HUMANS; KIDNEY DISEASES; OBESITY; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 56249115245     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328314b6ca     Document Type: Review

References (69)

1. Kakimoto Y, Akazawa S. Isolation and identification of N-G,N-G- and N-G,N′-G-dimethyl- arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosyl-galactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970; 245:5751-5758.
2. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
3. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109:1813-1818.
4. Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10:594-600.
5. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13:490-496.
6. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62:339-345.
7. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007; 53:273-283. A large clinical trial showing that ADMA concentration predicts all-cause and cardiovascular mortality in individuals with coronary artery disease independent of established and emerging cardiovascular risk factors.
8. Scalera F, Borlak J, Beckmann B, et al. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 2004; 24:1816-1822.
9. Wojciak-Stothard B, Torondel B, Tsang LY, et al. The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 2007; 120:929-942. This is the first study providing evidence that metabolism of ADMA regulates endothelial cell motility, an important factor in angiogenesis and vascular repair.
10. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46:1693-1701.
11. Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16:2449-2455.
12. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113-2117.
13. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23:1455-1459.
14. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109:172-177.
15. Kielstein JT, Bode-Boger SM, Hesse G, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25:1414-1418.
16. Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37:2024-2029.
17. Kielstein JT, Cooke JP. Should we measure asymmetric dimethylarginine in patients with coronary artery disease? Clin Chem 2007; 53:161-163.
18. Chang VW, Lauderdale DS. Income disparities in body mass index and obesity in the United States, 1971-2002. Arch Intern Med 2005; 165: 2122-2128.
19. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144:21-28.
20. Iseki K. Body mass index and the risk of chronic renal failure: the Asian experience. Contrib Nephrol 2006; 151:42-56.
21. Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17:1695-1702.
22. Sanches FM, Avesani CM, Kamimura MA, et al. Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis 2008; 52:66-73.
23. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14:469-477.
24. Dengel DR, Goldberg AP, Mayuga RS, et al. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 1996; 28:127-132.
25. McLaughlin T, Stuhlinger M, Lamendola C, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 2006; 91:1896-1900.
26. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287:1420-1426.
27. Sydow K, Mondon CE, Schrader J, et al. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 2008; 28:692-697. Preclinical study showing that ADMA reduces insulin sensitivity.
28. Spoto B, Parlongo RM, Parlongo G, et al. The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. J Nephrol 2007; 20:554-559. First preclinical study linking adipose tissue to ADMA metabolism.
29. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13:170-176.
30. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. J Am Soc Nephrol 2005; 16:2456-2461.
31. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003; 108:3042-3047.
32. Tanaka M, Sydow K, Gunawan F, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112:1549-1556.
33. Jacobi J, Sydow K, von Degenfeld G, et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111:1431-1438.
34. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13:198-203. Preclinical study that proves the concept that DDAH is the key regulator of ADMA metabolism using DDAH knockout mice.
35. Matsumoto Y, Ueda S, Yamagishi S, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007; 18:2176-2183. First preclinical study providing evidence that augmentation of DDAH activity improves cause and severity of a CKD model.
36. Hu T, Chouinard M, Cox AL, et al. FXR agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem 2006; 281:39831-39838.
37. Osanai T, Saitoh M, Sasaki S, et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42:985-990.
38. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87:99-105.
39. Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18:2161-2171.
40. Kielstein JT, Boger RH, Bode-Boger SM, et al. Low dialysance of asymmetric dimethylarginine (ADMA): in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004; 62:295-300.
41. Krzyzanowska K, Mittermayer F, Schnack C, et al. Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur J Clin Invest 2005; 35:208-213.
42. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in nondiabetic stage I chronic kidney disease. Kidney Int 2006; 70:781-787.
43. Stenvinkel P, Heimburger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15:953-960.
44. Boger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altem Med Rev 2005; 10:14-23.
45. Stys T, Stys A, Kelly P, Lawson W. Trends in use of herbal and nutritional supplements in cardiovascular patients. Clin Cardiol 2004; 27:87-90.
46. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295: 58-64.
47. Wilson AM, Harada R, Nair N, et al. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007; 116:188-195. A major clinical trial showing no benefit of chronic L-arginine supplementation in patients with peripheral arterial disease.
48. Furst P. Amino acid metabolism in uremia. J Am Coll Nutr 1989; 8:310-323.
49. Druml W, Kelly RA, May RC, Mitch WE. Abnormal cation transport in uremia. Mechanisms in adipocytes and skeletal muscle from uremic rats. J Clin Invest 1988; 81:1197-1203.
50. Tizianello A, De Ferrari G, Garibotto G, et al. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980; 65:1162-1173.
51. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 2008; 294:F1-F9. A comprehensive review on nitric oxide deficiency in CKD.
52. Lim VS, Bier DM, Flanigan MJ, Sum-Ping ST. The effect of hemodialysis on protein metabolism. A leucine kinetic study. J Clin Invest 1993; 91:2429-2436.
53. Wolfson M, Jones MR, Kopple JD. Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 1982; 21:500-506.
54. Kalousova M, Kielstein JT, Hodkova M, et al. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif 2006; 24:439-444.
55. Marescau B, Nagels G, Possemiers I, et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997; 46:1024-1031.
56. Kielstein JT, Salpeter SR, Bode-Boeger SM, et al. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function: a meta-analysis. Nephrol Dial Transplant 2006; 21:2446-2451.
57. Closs El, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y- carrier hCAT-2B. Nitric Oxide 1997; 1:65-73.
58. Bode-Boger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17:1128-1134.
59. Nijveldt RJ, Teerlink T, Van der HB, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 23-30.
60. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30.
61. Zoccali C, Maas R, Cutrupi S, et al. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 2007; 22:801-806. A small clinical study showing that the resolution of acute inflammation is characterized by an increase in the plasma concentration of ADMA, suggesting that ADMA suppression may actually serve in stimulating nitric oxide in acute inflammation.
62. Nicholls SJ, Wang Z, Koeth R, et al. Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation 2007; 116:2315-2324. A small clinical study on cardiogenic shock showing that ADMA levels were the strongest independent predictor of 30-day mortality.
63. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107:2998-3002.
64. Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297:1657-1666. A large clinical trial showing that L-NMMA did not reduce mortality rates in patients with refractory cardiogenic shock complicating MI.
65. Kielstein JT, Sydow K, Thum T. Tilarginine in patients with acute myocardial infarction and cardiogenic shock. JAMA 2007; 298:971-973.
66. Segarra G, Medina P, Vila JM, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 2001; 14:1142-1148.
67. Jung CS, Oldfield EH, Harvey-White J, et al. Association of an endogenous inhibitor of nitric oxide synthase with cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 2007; 107:945-950.
68. Seliger SL, Gillen DL, Longstreth WT Jr, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64:603-609.
69. Kielstein A, Tsikas D, Galloway GP, Mendelson JE. Asymmetric dimethylarginine (ADMA): a modulator of nociception in opiate tolerance and addiction? Nitric Oxide 2007; 17:55-59. A short review and outlook on possible involvement of ADMA in processes such as nociception and addiction.